Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders for Capricor Therapeutics, Inc., held on June 4, 2026, at the company's principal executive offices in San Diego, California. The filing details the voting outcomes for five proposals presented to shareholders.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and shareholder voting. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial performance details.
Material Changes and Voting Results
Of the 57,840,102 shares entitled to vote, 43,823,881 shares were present in person or by proxy. The results for the five proposals were as follows:
- Proposal 1 (Election of Directors): All eight nominees were elected. However, significant "Withheld" votes were recorded for several directors, ranging from approximately 5.3 million to 9.7 million shares, indicating notable shareholder dissent on specific board members.
- Proposal 2 (Ratification of Auditors): The appointment of Rose, Snyder & Jacobs LLP was ratified with 43,057,620 votes "For" versus 562,751 "Against".
- Proposal 3 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 24,336,434 votes "For" versus 6,244,316 "Against".
- Proposal 4 (Say-on-Pay Frequency): Shareholders voted for a "1 Year" frequency for future compensation votes, with 29,774,194 votes in favor.
- Proposal 5 (Officer Exculpation Amendment): The proposal to amend the Certificate of Incorporation regarding officer exculpation was not approved. It received 23,472,207 votes "For" and 6,433,198 votes "Against".
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies beyond the standard governance matters addressed at the meeting. The failure of Proposal 5 represents a specific governance outcome where shareholders rejected a proposed amendment to the company's charter.
Key Facts for Investor Verification
- Verify the specific reasons for the high number of "Withheld" votes for certain director nominees, particularly Frank Litvack, M.D., who received the highest number of withheld votes (9,678,907).
- Confirm the implications of the failed vote on the officer exculpation amendment (Proposal 5) and whether the company intends to resubmit the proposal.
- Review the definitive proxy statement filed on April 10, 2026, for detailed context on the director nominees and the exculpation amendment.
- Note that this filing does not contain financial performance data; verify current liquidity and cash runway through recent quarterly reports.